A Randomized, Open-label Phase III Intergroup Study: Effect of Adding Bevacizumab to Cross Over Fluoropyrimidine Based Chemotherapy (CTx) in Patients With Metastatic Colorectal Cancer and Disease Progression Under First-line Standard CTx/Bevacizumab Combination

drug protocol number
ML18147
drug sponsor
Roche
drug study
Bevacizumab
drug trial site
KFSH
drug status
Completed
drug phase